3-(benzaldehyde diethyl acetal)magnesium bromide

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-(benzaldehyde diethyl acetal)magnesium bromide
• 英文别名: 3-(benzaldehydediethylacetal)magnesium bromide；(3-(diethoxymethyl)phenyl)-magnesium bromide；(3-(diethoxymethyl)phenyl)magnesium bromide
• 化学式: C₁₁H₁₅BrMgO₂
• 分子量: 283.448
• InChiKey: HCEBUZLPRVUIOH-UHFFFAOYSA-M

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  15.0
• 可旋转键数：
  6.0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  18.46
• 氢给体数：
  0.0
• 氢受体数：
  2.0

反应信息

• 作为反应物：
  描述：

  3-(benzaldehyde diethyl acetal)magnesium bromide 在 盐酸 作用下， 以 四氢呋喃 、 水 为溶剂， 反应 3.5h， 生成 三(3-甲酰基苯基)铋
  参考文献：
  名称：

  铜介导的三价Arylbismuth试剂通过苯酚的O-芳基化反应合成高度官能化的二芳基醚

  摘要：

  高度官能化二芳基醚是由铜制备（II），乙酸介导的O-芳基化使用三价organobismuthanes酚的反应。该反应简单的条件下进行，并容许的官能团的广泛的多样性的苯酚和对有机铋试剂。通过在氧气气氛下进行反应，可以使用亚化学计量的催化剂。也报道了吡啶酮的N-芳基化。

  DOI：

  10.1002/chem.201303684

文献信息

• COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY
  申请人：CHIESI FARMACEUTICI S.p.A.

  公开号：US20160235734A1

  公开（公告）日：2016-08-18

  Compounds of formula I, defined herein, act both as muscarinic receptor antagonists and beta2 adrenergic receptor agonists and are useful for treating broncho-obstructive and inflammatory diseases.

  具有本公式I定义的化合物既作为毒蕈碱受体拮抗剂又作为β2肾上腺素能受体激动剂，并且用于治疗支气管阻塞和炎症性疾病。
• Palladium-Catalyzed Cross-Coupling Reaction of Functionalized Aryl- and Hetero­arylbismuthanes with 2-Halo(or 2-Triflyl)­azines and -diazines
  作者：Pauline Petiot、Alexandre Gagnon

  DOI：10.1002/ejoc.201300850

  日期：2013.8

  The palladium-catalyzed cross-coupling of highly functionalized organobismuthanes with 2-halo(or 2-triflyl)pyridines, -pyrimidines, -pyrazines, and -pyridazines is reported. The reaction tolerates numerous functional groups, including aldehydes. The synthesis of a shelf-stable (formylphenyl)bismuth reagent and its use in a cross-coupling reaction is also described.

  钯催化的高度官能化的有机铋与 2-卤代（或 2-三氟甲基）吡啶、-嘧啶、-吡嗪和-哒嗪的交叉偶联被报道。该反应耐受许多官能团，包括醛。还描述了货架稳定（甲酰基苯基）铋试剂的合成及其在交叉偶联反应中的用途。
• Compounds having muscarinic receptor antagonist and BETA2 adrenergic receptor agonist activity
  申请人：CHIESI FARMACEUTICI S.p.A.

  公开号：US10004728B2

  公开（公告）日：2018-06-26

  Compounds of formula I, defined herein, act both as muscarinic receptor antagonists and beta2 adrenergic receptor agonists and are useful for treating broncho-obstructive and inflammatory diseases.

  本文定义的式 I 化合物既是毒蕈碱受体拮抗剂，又是β2 肾上腺素能受体激动剂，可用于治疗支气管阻塞性疾病和炎症性疾病。
• 2-(Phenylsulfonyl)quinoline N -hydroxyacrylamides as potent anticancer agents inhibiting histone deacetylase
  作者：Hsueh-Yun Lee、Chih-Yi Chang、Chih-Jou Su、Han-Li Huang、Samir Mehndiratta、Yuh-Hsuan Chao、Chia-Ming Hsu、Sunil Kumar、Ting-Yi Sung、Yi-Zhen Huang、Yu-Hsuan Li、Chia-Ron Yang、Jing-Ping Liou

  DOI：10.1016/j.ejmech.2016.06.023

  日期：2016.10

  This study reports the design and synthesis of 2-(phenylsulfonyl)quinoline N-hydroxyacrylamides (8a-k). Structure-activity relationship studies focusing on regio-effect of N-hydroxyacrylamide moiety and influence of the sulfonyl linker revealed that N-hydroxy-3-[3-(quinoline-2-sulfonyl)-phenyl]-acrylamide (8f) showed remarkable enzymatic and cellular activity. The GI(50) values of 8f for HL-60, HCT116, PC-3, and A549 cells were found to be 0.29, 0.08, 0.15, and 0.27 mu M, respectively. The compounds are therefore more potent than FDA approved PXD-101 and SAHA. They also have an effect on the acetylation degree of histone H3 and alpha-tubulin. In in vivo studies, 8f showed marked inhibition of the growth of HCT116 xenografts. (C) 2016 Published by Elsevier Masson SAS.
• US9579314B2
  申请人：——

  公开号：US9579314B2

  公开（公告）日：2017-02-28